Transforming short-term spend into long-term value – Mark Ward explains:

Why is Q4 such a critical time for pharma and biotech teams from a commercial perspective?

Q4 is pivotal because it’s the final opportunity to:

• Maximise budget utilisation before year-end.
• Drive HCP engagement ahead of the holiday slowdown.
• Set the tone for Q1 with momentum-building activities.
• Close strategic gaps in brand awareness, education, or access. It’s also when performance reviews and planning for the next year intensify, making it a key window to demonstrate commercial impact.

What are the biggest mistakes you see brands make with their remaining Q4 budget?

Some common pitfalls include:

• Rushed, reactive spending without strategic alignment.
• Over-investing in tactics that don’t deliver measurable ROI.
• Neglecting compliance timelines, especially for medical content.
• Missing cross-functional collaboration, leading to siloed efforts.
• Failing to capture learnings for future planning.

What quick-win opportunities still exist for engaging HCPs in Q4?

Quick wins include:

• Targeted digital campaigns (e.g., email, programmatic, social) with clear value propositions.
• Virtual peer-to-peer engagements or micro-webinars.
• Rep-triggered content via CRM tools to personalise outreach.
• End-of-year clinical updates or summaries that help HCPs prepare for 2026.
• Omnichannel refreshes to optimise existing assets for better reach.

How can teams turn short-term year-end activity into long-term value in 2026?

By:

• Capturing engagement data to inform segmentation and personalization.
• Testing new channels or messages and scaling what works.Building relationships that carry into Q1 (e.g., advisory boards, KOL connections).
• Documenting performance to support budget justification and strategic planning.
• Aligning with medical and market access teams to ensure continuity.

What differentiates Uniphar Commercial?

Uniphar Commercial stands out through:

• Integrated solutions across engagement, access, and education.
• Deep HCP insights from proprietary data and analytics.
• Agile execution with compliance-first thinking.
• Pan-European reach with local expertise.
• Proven track record of driving measurable outcomes for pharma brands.

Can you share a real example where Q4 activity led to success in the following year?

A mid-sized biotech used Q4 to launch a targeted omnichannel campaign for a newly approved therapy. They:

• Engaged HCPs with rep-triggered emails and webinars.
• Used data analytics to refine messaging.
• Captured engagement metrics to inform Q1 strategy.

Result: In Q1, they saw a 35% increase in prescribing intent and expanded their reach to previously low-engagement segments. The Q4 groundwork directly fuelled their Q1 success.

If you could give one piece of advice to brand leaders planning for 2026, what would it be?

Plan with agility, execute with precision. Build flexible strategies that allow for rapid iteration based on real-world data. Invest in omnichannel infrastructure, HCP insights, and cross-functional alignment to ensure your brand is not just visible, but valuable in 2026.

Partner with Uniphar Commercial to transform short-term spend into long-term value.